Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewJH 295 is an irreversible Nek2 inhibitor (IC50=770 nM). Inhibits Nek2 via alkylation of residue Cys22. Displays 5-fold selectivity for Nek2 over Cdk1. Exhibits no significant effect on Aurora B or Plk1 kinases, bipolar spindle assembly or spindle assembly checkpoint. Cell permeable.
M. Wt | 320.35 |
Formula | C18H16N4O2 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 1311143-71-1 |
PubChem ID | 53262909 |
InChI Key | ORKOHXAJFGRZCL-LCYFTJDESA-N |
Smiles | O=C2NC1=CC=C(NC(C#C)=O)C=C1/C2=C/C3=C(C)N=C(CC)N3 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 32.03 | 100 |
The following data is based on the product molecular weight 320.35. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 3.12 mL | 15.61 mL | 31.22 mL |
5 mM | 0.62 mL | 3.12 mL | 6.24 mL |
10 mM | 0.31 mL | 1.56 mL | 3.12 mL |
50 mM | 0.06 mL | 0.31 mL | 0.62 mL |
References are publications that support the biological activity of the product.
Henise et al (2011) Irreversible Nek2 kinase inhibitors with cellular activity. J.Med.Chem. 54 4133 PMID: 21627121
If you know of a relevant reference for JH 295, please let us know.
Keywords: JH 295, JH 295 supplier, JH295, Nek2, inhibitor, inhibits, irreversible, alkylation, Kinase, 4322, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for JH 295. Do you know of a great paper that uses JH 295 from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review JH 295 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.